Hemophagocytic Syndrome: A Misleading Complication of Visceral Leishmaniasis in Children---A Series of 12 Cases

PEDIATRICS ◽  
2000 ◽  
Vol 106 (4) ◽  
pp. e58-e58 ◽  
Author(s):  
M.-H. Gagnaire ◽  
C. Galambrun ◽  
J. L. Stephan
2006 ◽  
Vol 73 (5) ◽  
pp. 445-446 ◽  
Author(s):  
Shilpi Agarwal ◽  
Shashi Narayan ◽  
Sunita Sharma ◽  
Eram Kahkashan ◽  
A. K. Patwari

2021 ◽  
Author(s):  
SHULAN SHI ◽  
HENG ZHAO ◽  
MINGBIAO MA ◽  
XIAOJUAN LI ◽  
JI XU ◽  
...  

Abstract Background: Visceral leishmaniasis related-hemophagocytic lymphohistiocytosis (VL-HLH) is a hemophagocytic syndrome caused by Leishmania infection. VL-HLH is rare, especially in nonendemic areas where the disease is severe, and mortality rates are high. The key to diagnosing VL-HLH is to find the pathogen; therefore, the Leishmania must be accurately identified for timely clinical treatment.Case presentationWe retrospectively analyzed the clinical data, laboratory examination results and bone marrow cell morphology of two children with VL-HLH diagnosed via bone marrow cell morphology between July 2017 and January 2021 at Kunming Children’s Hospital of Yunnan, China.Two cases suspected of having malignant tumors at other hospitals and who had undergone ineffective long-term treatment were transferred to Kunming Children’s Hospital. They had repeated fevers, pancytopenia, hepatosplenomegaly, hypertriglyceridemia, and hypofibrinogenemia over a long period and met the HLH-2004 standard. Their HLH genetic test results were negative, and primary HLH was excluded. Both children underwent chemotherapy as per the HLH-2004 chemotherapy regimen , but it was ineffective and accompanied by serious infections. We found Leishmania amastigotes in their bone marrow via morphological examination of their bone marrow cells, which showed hemophagocytic cells; thus, the children were diagnosed with VL-HLH. After being transferred to a specialty hospital for treatment, the condition was well-controlled. Conclusion: Morphological examination of the bone marrow cells played an important role in diagnosing VL-HLH. When clinically diagnosing secondary HLH, VL-HLH should be considered in addition to common pathogens, especially in patients for whom HLH-2004 chemotherapy regimens are ineffective. For infants and young children, bone marrow cytology examinations should be performed several times and as early as possible to find the pathogens to reduce potential misdiagnoses.


2015 ◽  
Vol 34 (12) ◽  
pp. 1311-1314 ◽  
Author(s):  
Elizabeth F. Daher ◽  
Laio L. L. Lima ◽  
Ana Patrícia F. Vieira ◽  
Lucas S. Nascimento ◽  
Douglas S. Soares ◽  
...  

2009 ◽  
Vol 28 (8) ◽  
pp. 753-754 ◽  
Author(s):  
Andrea Martín ◽  
Laura Marques ◽  
Pere Soler-Palacín ◽  
Isabel Caragol ◽  
Manuel Hernandez ◽  
...  

2016 ◽  
Vol 10 (01) ◽  
pp. 103-108 ◽  
Author(s):  
Maria Scalzone ◽  
Antonio Ruggiero ◽  
Stefano Mastrangelo ◽  
Giovanna Trombatore ◽  
Vita Ridola ◽  
...  

Hemophagocytic lymphohistiocytosis is a potentially fatal disorder resulting from excessive activation and non-malignant proliferation of T lymphocytes and macrophages. Neoplasms, autoimmune disorders and systemic infections can cause secondary hemophagocytic syndrome. The association of hemophagocytic syndrome and visceral leishmaniasis is rarely found in childhood.  We report a case of an infant affected by hemophagocytic lymphohistiocytosis secondary to visceral leishamniasis and describe all cases of hemophagocytic syndrome associated with visceral leishamniasis in childhood reported in literature, focusing on clinical manifestation, diagnosis and treatment.


2021 ◽  
Vol 8 ◽  
Author(s):  
Danfeng Ren ◽  
Wenya Cao ◽  
Xiaojing Liu ◽  
Qunying Han ◽  
Wanhu Fan ◽  
...  

Background: No consensus has been reached regarding the optimal therapy for visceral leishmaniasis (VL), which affects ~12 million people worldwide.Case Presentation: This report described four cases of VL encountered in the First Affiliated Hospital of Xi'an Jiaotong University between October 2019 and December 2020. Of the four patients, one patient experienced relapse after antimonial treatment, and the remaining patients had primary VL (including one patient with impaired kidney function and one patient with hemophagocytic syndrome). All patients received a novel treatment protocol, namely the low-dose L-AmB therapy, which was characterized by a low initial dose, cautious dose escalation, and low-dose therapy as maintenance. All patients were cured without severe complications, and there was no further recurrence during follow-up.Conclusions: This case series demonstrated the safety and efficacy of the low-dose L-AmB therapy for VL patients, providing novel treatment protocol for the VL.


1997 ◽  
Vol 19 (2) ◽  
pp. 14-16 ◽  
Author(s):  
Pilar Cortés ◽  
Neus Cardeñosa ◽  
Carmen Muñoz ◽  
Ignaci Durán ◽  
Rubén Leta ◽  
...  

2006 ◽  
Vol 10 (1) ◽  
pp. 85-86 ◽  
Author(s):  
Badreddine Kilani ◽  
Lamia Ammari ◽  
Fakher Kanoun ◽  
Taoufik Ben Chaabane ◽  
Sami Abdellatif ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document